Moreover, an increased activation of the mTOR cell signaling pathway was described in trabectedin-resistant clear cell carcinoma cell lines, while trabectedin treatment induced a prolonged stimulation of mTOR in the same model. This evidence concerns the gene MTOR and clear cell adenocarcinoma.